Getinge AB stock (SE0000202624): shares little changed as investors eye analyst views after Q1 update

Getinge AB shares traded broadly stable on Nasdaq Stockholm at the start of the week, as the Swedish medtech group digests its April Q1 2026 earnings release and investors focus on how analysts are positioning the stock in the wake of recent margin and order trends.

Getinge AB shares were broadly stable in Stockholm trading on Monday, with the Swedish medtech group continuing to trade around recent levels after publishing its first-quarter 2026 results on 04/22/2026 and updating the market on demand trends across its main healthcare technology segments, according to Nasdaq Stockholm data as of 06/01/2026 and the company’s investor relations materials.

The stock, listed on Nasdaq Stockholm under the ticker GETI B, has been reacting in recent weeks to Getinge’s April Q1 2026 earnings release, in which the Gothenburg-based company reported revenue trends, profitability metrics and order development for the quarter in Swedish krona, according to the Q1 2026 interim report published on 04/22/2026 on the Getinge investor relations website.

From a home-country perspective, Getinge’s listing on Nasdaq Stockholm keeps it firmly in focus for Swedish equity investors who benchmark against indices such as OMXS30 and broader Swedish medtech peers, while the primary liquidity in the share is in Swedish krona on the Stockholm exchange, according to Nasdaq OMX Nordic’s listing overview for Getinge as of 06/01/2026.

For German-speaking investors, Getinge is also tradable on German trading venues such as Tradegate in euro, where the stock typically follows the lead of the Swedish home-market price in SEK, according to price overviews from German trading platforms referencing Getinge AB as of 06/01/2026.

While Monday’s price action did not show a pronounced move in percentage terms, market participants remain focused on how Getinge’s Q1 2026 figures compare with both prior-year performance and market expectations, and how analysts at Nordic and international banks interpret the latest order, margin and cash flow developments set out in the 04/22/2026 interim report.

As of: 06/01/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Getinge B
• Sector/industry: Medical technology and healthcare equipment
• Headquarters/country: Gothenburg, Sweden
• Core markets: Europe, North America, Asia-Pacific and other global healthcare markets
• Key revenue drivers: Acute care therapies, surgical workflows, life science and related healthcare systems and services
• Home exchange/listing venue: Nasdaq Stockholm (GETI B)
• Trading currency: SEK

Getinge AB: core business model

Getinge AB focuses on supplying hospitals and life science institutions worldwide with medical technology, infection control and workflow solutions that generate revenue primarily through equipment sales, associated consumables and service contracts for acute care, surgical and life science applications.

What banks and research houses say about Getinge AB

No verified analyst coverage was identified at the time of publication.

Conclusion

With Getinge AB trading fairly steadily on Nasdaq Stockholm after its 04/22/2026 Q1 2026 update, the near-term focus for investors remains on how the Swedish medtech group can translate its order intake and margin initiatives into sustainable earnings performance. The absence of clearly documented, up-to-date analyst ratings in public sources at the time of writing leaves investors leaning more heavily on company disclosures and peer comparisons when assessing valuation and risk for the Getinge share.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.